1. HANA Audit Update for SSG
Hannah Marder
Cancer Manager UH Bristol

2. 2014-16 data All submitted in full to HANA
High completeness on all fields (UH Bristol and RUH)
Some false alarms raised by HANA team as forgot not to include recurrences in staging
Some fields were excluded due to technical issues, although UH Bristol had managed to upload them via a work around

3. Fields focussed on
The fields HANA pushed for high completeness on were:
Laterality
Histology code from biopsy
Care plan date, intent and first treatment type
TNM, performance status and comorbidity index
CNS present at diagnosis
Procedure code and surgeon code
Radiotherapy treatment target body part
Chemotherapy drug type

4. 2017 data
The first ‘proper’ HANA submission will relate to patients diagnosed between 01/11/2016 and 31/10/ No deadline is specified
We expect to submit a high degree of completeness against the key fields
Separate meetings have been held with AHP teams to help with their data collection

5. 2017 data - responsibilities
UH Bristol will take responsibility for the data of patients diagnosed at UH Bristol, Weston, Yeovil, and NBT
RUH will be responsible for data of patients diagnosed at RUH
UH Bristol will also ensure complete treatment information for patients diagnosed at RUH but treated at UH Bristol

6. Important changes from DAHNO
CNS contact is taken from the diagnosis page
Specific boxes for recording restorative dentistry opinion and resective pathology discussion at MDT
Must set the ‘careplan agreed’ box on the MDT record to ‘yes’ for the information to pull
First seen date recorded separately from the usual place

7. DAHNO 14-16 Treatment intent vs cancer type
Cancer site
Curative
No active treatment
Non Curative
Not recorded
Grand Total
% Curative
Bones of jaw 14 4 18
78%
Hypopharynx and larynx 72 1 11 85
85%
Nasopharynx and sinus 34 39
87%
Oral cavity excl oropharynx
121 6
128
95%
Oropharynx inc tonsil 88 13
101
Salivary and parotid glands 27 28
96%
356 3
399
89%
Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

8. DAHNO 14-16 Stage at diagnosis vs cancer type
Cancer site
Not staged
TXN0M0
T1/2N0M0
T3/4N0M0
Nodes involved
Metastatic
Grand Total
Bones of jaw 10 8 18
Hypopharynx and larynx 2 39 22 20 85
Nasopharynx 5 6 14 12
Oral cavity 84 19 1
128
Oropharynx 7 69
101
Salivary and parotid glands 21 28 11
172 74
136 4
399
Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

9. DAHNO 14-16 First treatment vs cancer type
Cancer site
Chemorad
Chemo
Other
Pal care
Surgery RT
Not stated
Grand Total
Bones of jaw 3 14 1 18
Hypopharynx and larynx 9 5 36 30 2 85
Nasopharynx 4 23 7 39
Oral cavity 8
104
128
Oropharynx 29 54 12
101
Salivary and parotid glands 21 28 48 19 13
252 59
399
Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA

10. DAHNO 14-16 Performance status and comorbidity index vs cancer type
Cancer site
PS 0
PS 1
PS 2
PS 3
PS 4
Not stated
Grand Total
Bones of jaw 11 1 3 18
Hypopharynx and larynx 45 8 22 4 2 85
Nasopharynx 20 12 39
Oral cavity 93
128
Oropharynx 69 5
101
Salivary and parotid glands 25 28
263 21 80 10 17
399
Cancer site
None
Mild
Moderate
Severe
Not stated
Grand Total
Bones of jaw 12 1 3 18
Hypopharynx and larynx 35 23 6 85
Nasopharynx 20 8 9 39
Oral cavity 83 27 4 11
128
Oropharynx 62 2 15
101
Salivary and parotid glands 7 28
230 79 63
399
Primary only. Full MDT data (RUH and Bristol). Source – DAHNO/HANA